Paradigm Biocapital Advisors LP Janux Therapeutics, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,329,909 shares of JANX stock, worth $84.9 Million. This represents 4.61% of its overall portfolio holdings.
Number of Shares
3,329,909
Previous 3,515,986
5.29%
Holding current value
$84.9 Million
Previous $188 Million
52.24%
% of portfolio
4.61%
Previous 7.18%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
188Shares Held
57.4MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$285 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$117 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$93.2 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$59.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$58.1 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.06B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...